[{"orgOrder":0,"company":"Eisai","sponsor":"Washington University School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"E2814","moa":"||Microtubule-associated protein tau (MAPT)","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Washington University School of Medicine","highestDevelopmentStatusID":"9","companyTruncated":"Eisai \/ Washington University School of Medicine"},{"orgOrder":0,"company":"Eisai Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"E2814","moa":"Microtubule-associated protein tau (MAPT)","graph1":"Neurology","graph2":"Phase II","graph3":"Eisai Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eisai Inc \/ Undisclosed"},{"orgOrder":0,"company":"Eisai Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"E2814","moa":"Microtubule-associated protein tau (MAPT)","graph1":"Neurology","graph2":"Phase II","graph3":"Eisai Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eisai Inc \/ Undisclosed"},{"orgOrder":0,"company":"Eisai Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"E2814","moa":"Microtubule-associated protein tau (MAPT)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Eisai Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eisai Inc \/ Undisclosed"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Alzheimer's Association | National Institute on Aging | Accelerating Medicines Partnership | Eisai Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"E2814","moa":"Microtubule-associated protein tau (MAPT)","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Alzheimer's Association | National Institute on Aging | Accelerating Medicines Partnership | Eisai Inc","highestDevelopmentStatusID":"9","companyTruncated":"Washington University School of Medicine \/ Alzheimer's Association | National Institute on Aging | Accelerating Medicines Partnership | Eisai Inc"}]